Servier Egypt boosts local production, launches Cancer Program

EGYPT—Servier Egypt, a subsidiary of the global Servier Group, has celebrated its Platinum Jubilee in Egypt with the inauguration of a new state-of-the-art production line and the launch of a groundbreaking health access initiative called “Access Cancer Treatment (ACT) for Children.”

These accomplishments coincide with the celebration of Servier’s 70 years of global success.

Influential figures, including Dr. Ali El Ghamrawy, Head of the Egyptian Drug Authority, and Dr. Hesham Stait, Head of the Egyptian Authority for Unified Procurement, attended the event.

Dr. Stait emphasized the vital role of public-private partnerships in advancing Egypt’s Vision 2030.

He particularly highlighted the importance of localized production, increased exports, and innovative healthcare solutions in driving national progress.

Servier Egypt has been a trusted partner in Egypt’s healthcare development for over five decades.

The company has continually focused on sustainable growth, innovation, and expanding access to life-saving treatments.

Servier Egypt produces 25 million medication boxes annually for Egyptian patients, contributing significantly to the country’s healthcare needs.

Located in the 6th of October city, Servier Egypt’s pharmaceutical site houses two advanced manufacturing facilities, part of a global network of eight Servier Group production sites.

Established in 1994, the facility began with a production capacity of 5 million boxes annually.

Today, it has expanded to produce 25 million boxes, 90% of which serve the local market and 10% are exported to nine countries in Africa and the Middle East.

In total, Servier has invested over EGP 1.6 billion (US$31.821 million) in Egypt, including EGP 370 million US$7.358 million) dedicated to 11 key projects to enhance capacity, quality, safety, and digitalization.

These efforts include installing solar panels, a wastewater treatment system, and a new high-speed packaging line.

Servier aims to produce 50 million boxes annually by 2030 as part of its growth plans, expanding its production capacity to meet local demand and increase regional exports.

Samy Sinnuqrut, the General Manager of Servier Egypt, said the company’s growth reflects its strong commitment to Egypt’s Vision 2030.

He highlighted that Servier’s local production and innovation investments aim to improve patient access to advanced treatments and contribute to Egypt’s broader economic and healthcare goals.

The company currently offers a diverse portfolio of 34 medicines, addressing key therapeutic areas such as cardiology, diabetes, and heart failure.

 Servier has also made notable strides in oncology, introducing life-changing treatments for metastatic colorectal and pancreatic cancer in Egypt—two areas of critical medical need.

The company is working to bring even more advanced oncology treatments to Egypt in the near future.

In addition to its focus on medical innovation, Servier Egypt launched the “Access Cancer Treatment (ACT) for Children” initiative.

This program aims to address childhood cancer disparities by improving access to quality medical care, training healthcare professionals, and expanding the availability of life-saving treatments.

Sinnuqrut emphasized that the ACT for Children initiative is aligned with Servier’s 2030 ambition to make a positive social impact and ensure that children everywhere receive the care they need.

Through these initiatives and investments, Servier Egypt continues to reinforce its role as a leader in both healthcare innovation and economic development, driving progress for patients across Egypt and beyond.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on our WhatsApp channel for updates.